ZACHARON PHARMACEUTICALS, INC.

Company Information
Address 5626 Oberlin Drive
San Diego, CA, 92121-


Information

DUNS: 68188411

# of Employees: N/A


Ownership Information

Hubzone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Development of a Novel Biomarker for Mucopolysaccharidosis I, II, and VI

    Amount: $335,739.00

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a biomarker capable of definitively diagnosing and monitoring response to therapy in patients with Mucopolysaccharidosis (M ...

    SBIRPhase I2012Department of Health and Human Services
  2. Development of a Small Molecule Therapy for Metachromatic Leukodystrophy

    Amount: $296,236.00

    DESCRIPTION (provided by applicant): The objective of this Phase I SBIR proposal is to develop a central nervous system penetrant (CNS) small molecule therapy for Metachromatic Leukodystrophy (MLD). W ...

    SBIRPhase I2012Department of Health and Human Services
  3. A Novel Small Molecule Therapy for Tay-Sachs and Sandhoff Diseases

    Amount: $342,896.00

    DESCRIPTION (provided by applicant): Project Summary Using a novel high-throughput screening approach, we have recently identified the first selective small molecule inhibitors of the biosynthes ...

    SBIRPhase I2011Department of Health and Human Services
  4. Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis

    Amount: $2,998,889.00

    DESCRIPTION (provided by applicant): Project Summary The studies proposed in this application are aimed at progressing an innovative approach to treating mucopolysaccharidoses (MPS) toward clini ...

    SBIRPhase II2011Department of Health and Human Services
  5. Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis

    Amount: $339,513.00

    DESCRIPTION (provided by applicant): Project Summary The studies proposed in this application will test the feasibility of treating mucopolysaccharidosis (MPS) through a novel therapeutic approa ...

    SBIRPhase I2010Department of Health and Human Services
  6. Structure-activity relationship study of an inhibitor of tumor metastasis

    Amount: $188,112.00

    DESCRIPTION (provided by applicant): A large number of deaths from epithelial tumors of the breast, prostate, lung, ovary, liver, and kidney are caused by metastatic spread of the primary tumor. Unfor ...

    SBIRPhase I2008Department of Health and Human Services
  7. Development of Novel Inhibitors of Ganglioside Biosynthesis

    Amount: $1,455,560.00

    DESCRIPTION (provided by applicant): The underlying hypothesis of this proposal is that inhibitors of ganglioside biosynthesis will prevent or slow the growth of neural crest-derived tumors (neuroblas ...

    SBIRPhase II2008Department of Health and Human Services
  8. Development of a cell-based screen for inhibitors of ganglioside biosynthesis

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The underlying hypothesis of this proposal is that inhibitors of ganglioside biosynthesis will prevent or slow the growth of neural crest-derived tumors (neuroblas ...

    SBIRPhase I2006Department of Health and Human Services
  9. Chondroitin Sulfate Inhibitor Screen for Neural-Regeneration Drugs

    Amount: $114,868.00

    DESCRIPTION (provided by applicant): In accordance with the National Institute of Neurological Disorders and Stroke (NINDS) priorities, the goal of this proposal is to develop a system to discover dru ...

    SBIRPhase I2006Department of Health and Human Services
  10. Inhibitors of Heparan Sulfate Biosynthesis and Cancer

    Amount: $196,245.00

    DESCRIPTION (provided by applicant): The underlying hypothesis of this proposal is that inhibitors of heparan sulfate biosynthesis will slow tumor growth. Genetic and pharmacological data has valid ...

    SBIRPhase I2006Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government